A Biocell Portfolio Development company that commercializes advanced cell therapy research in order to accelerate the development within regenerative medicine and make groundbreaking treatments more accessible and affordable.
- Gunnar Forssell, former strategy lead at Merck, joins Takura 30 juni, 2021
- TAKURA presents at Financial Hearings 23 mars, 2021
- Takura acquires Polybiocept GmbH 14 juli, 2020
- Takura joins forces with Abu Dhabi 26 september, 2019